

Lenvatinib (Lenvima®) - DTC Therapy

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	HSE approved Reimbursement Status*
Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.	C73	00295a	CDS 01/01/2016

*This is for post 2012 indications only

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

Lenvatinib (Lenvima®) is taken once daily continuously until disease progression or unacceptable toxicity develops.

Drug	Dose	Route	Cycle
Lenvatinib (Lenvima®)	24mg once daily	PO	Continuous therapy
<p>The capsules should be taken at about the same time each day, with or without food. Lenvatinib (Lenvima®) capsules can be swallowed whole with water or administered as a suspension prepared by dispersing the whole capsule(s) in water, apple juice or milk. If administered via a feeding tube, then the suspension should be prepared using water. Place the capsule(s) corresponding to the prescribed dose (up to 5 capsules) in a small container (approximately 20mL (4 tsp) capacity) or oral syringe (20mL); do not break or crush the capsules. Add 3 mL of liquid to the container or oral syringe, wait 10 minutes for the capsule shell to disintegrate, then stir or shake the mixture for 3 minutes until the capsules are fully disintegrated. Administer the contents directly into the mouth or via feeding tube. Add an additional 2 mL of liquid to the container and administer.</p> <p>If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.</p>			

ELIGIBILITY:

- Indication as above
- ECOG status 0-2
- Measurable, pathologically confirmed differentiated thyroid cancer, evidence of iodine-131–refractory disease
 - at least one measurable lesion without iodine uptake on any iodine-131 scan,
 - at least one measurable lesion that had progressed according to the RECIST criteria within 12 months after iodine-131 therapy despite iodine-131 avidity at the time of treatment,
 - or cumulative activity of iodine-131 that was >600 mCi), and independently reviewed radiologic evidence of progression within the previous 13 months
- May have received none or one prior treatment regimen with a tyrosine kinase inhibitor
- Adequate haematological, renal and liver status

NCCP Regimen: Levatinib (Lenvima®) - DTC therapy	Published: 12/01/2016 Review: 12/04/2029	Version number: 6
Tumour Group: Head and Neck NCCP Regimen Code: 00295	IHS/ISMO Contributor: Dr Liam Grogan Prof Maccon Keane	Page 1 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

- Thyroid hormone suppression therapy with thyroid stimulating hormone (TSH) level \leq 0.50mIU/L

EXCLUSIONS:

- Hypersensitivity to lenvatinib (Lenvima®) or any of the excipients
- Uncontrolled hypertension
- Breast-feeding
- Proteinuria \geq 1g/24 hours or significant cardiovascular or gastrointestinal dysfunction

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist

TESTS:

Baseline tests:

- FBC, renal and liver profiles
- Coagulation, proteinuria $<$ 1g/24 hours, TSH
- Blood pressure
- ECG

Regular tests:

- FBC, renal profile, coagulation, proteinuria, TSH every 28 days
- Liver profile every 2 weeks for the first 2 months and monthly thereafter during treatment*
- Calcium levels monthly
- Blood pressure should be monitored after 1 week of treatment with lenvatinib (Lenvima®), then every 2 weeks for the first 2 months, and monthly thereafter
- ECG as clinically indicated

*See Adverse Reactions/Regimen Specific Complications for more information

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.
- Patients of age \geq 75 years, of Asian race, with comorbidities (such as hypertension, and hepatic or renal impairment), or body weight below 60 kg appear to have reduced tolerability to lenvatinib (Lenvima®)
- Management of suspected adverse drug reactions may require dose interruption, adjustment or discontinuation of lenvatinib (Lenvima®) therapy
- Optimal medical management for nausea, vomiting and diarrhoea should be initiated prior to any interruption or dose reduction of lenvatinib (Lenvima®)
- Gastrointestinal toxicity should be actively managed in order to reduce the risk of development of renal impairment or failure
- Table 1 shows the dose modifications for lenvatinib (Lenvima®)

NCCP Regimen: Levatinib (Lenvima®) - DTC therapy	Published: 12/01/2016 Review: 12/04/2029	Version number: 6
Tumour Group: Head and Neck NCCP Regimen Code: 00295	IHS/ISMO Contributor: Dr Liam Grogan Prof Maccon Keane	Page 2 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Table 1: Dose modification table for lenvatinib (Lenvima®) therapy

Dose level	Daily Dose
Recommended daily dose	24mg orally once daily
First dose reduction	20mg orally once daily
Second dose reduction	14mg orally once daily
Third dose reduction	10mg orally once daily*
*Further dose reductions should be considered on an individual patient basis as limited data are available for doses below 10mg	

Renal and hepatic impairment

Table 2: Dose modification of lenvatinib (Lenvima®) in renal and hepatic impairment

Renal impairment:		Hepatic Impairment	
CrCl (mL/min)	Dose	Child Pugh A/B	No dose adjustment is needed
≥ 30	No dose adjustment is needed	Child Pugh C	14mg once daily
< 30	14 mg once daily		
Haemodialysis	50% of the original dose may be considered		
Dose modifications from Giraud et al 2023 and SmPC			

Management of adverse events:

Table 3: Management of treatment with lenvatinib (Lenvima®) related hypertension

Blood Pressure (BP) level	Recommended Action
Systolic BP ≥140 mmHg up to <160 mmHg OR Diastolic BP ≥90 mmHg up to <100 mmHg	Continue lenvatinib (Lenvima®) and initiate antihypertensive therapy, if not already receiving OR Continue lenvatinib (Lenvima®) and increase the dose of the current antihypertensive therapy or initiate additional antihypertensive therapy
Systolic BP ≥160 mmHg OR Diastolic BP ≥100 mmHg despite optimal antihypertensive therapy	1. Withhold lenvatinib (Lenvima®) 2. When systolic BP ≤150 mmHg, diastolic BP ≤95mmHg, and patient has been on a stable dose of antihypertensive therapy for at least 48 hours, resume lenvatinib (Lenvima®) at a reduced dose (see Table 1)
Life-threatening consequences (malignant hypertension, neurological deficit, or hypertensive crisis)	Urgent intervention is indicated. Discontinue lenvatinib (Lenvima®) and institute appropriate medical management.

NCCP Regimen: Lenvatinib (Lenvima®) - DTC therapy	Published: 12/01/2016 Review: 12/04/2029	Version number: 6
Tumour Group: Head and Neck NCCP Regimen Code: 00295	IHS/ISMO Contributor: Dr Liam Grogan Prof Maccon Keane	Page 3 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Table 4: Dose modification schedule based on adverse events

Adverse Reaction	Severity	Recommended dose modification
Proteinuria	≥ 2 gm/24 hours (urine dipstick)	Interrupt until resolved to < 2gm/24 hours
Nephrotic syndrome		Discontinue
Renal impairment or failure	Grade 3	Interrupt until resolved to Grade 0-1 or baseline
	Grade 4*	Discontinue
Cardiac dysfunction	Grade 3	Interrupt until resolved to Grade 0-1 or baseline
	Grade 4	Discontinue
Posterior reversible encephalopathy syndrome (PRES)/ Reversible posterior leukoencephalopathy syndrome (RPLS)	Any grade	Interrupt Consider resuming at reduced dose if resolves to Grade 0-1.
Hepatotoxicity	Grade 3	Interrupt until resolved to to Grade 0-1 or baseline
	Grade 4*	Discontinue
Arterial thromboembolism	Any grade	Discontinue
Haemorrhage	Grade 3	Interrupt until resolved to Grade 0-1
	Grade 4	Discontinue
GI perforation or fistula	Grade 3	Interrupt until resolved to Grade 0-1 or baseline
	Grade 4	Discontinue
Non-GI fistula	Grade 4	Discontinue
QT interval prolongation	>500ms	Interrupt until resolved to <480ms or baseline
Diarrhoea	Grade 3	Interrupt until resolved to Grade 0-1 or baseline
	Grade 4 (despite medical management)	Discontinue

*Grade 4 laboratory abnormalities judged to be non-life-threatening, may be managed as severe reactions (e.g. Grade 3)

NCCP Regimen: Levatinib (Lenvima®) - DTC therapy	Published: 12/01/2016 Review: 12/04/2029	Version number: 6
Tumour Group: Head and Neck NCCP Regimen Code: 00295	IHS/ISMO Contributor: Dr Liam Grogan Prof Maccon Keane	Page 4 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

Moderate for dose >12mg/day (**Refer to local policy**)

Minimal to low for dose ≤12mg/day (**Refer to local policy**).

PREMEDICATIONS: Not usually required

OTHER SUPPORTIVE CARE:

- Anti-diarrhoeal treatment (**Refer to local policy**).
- Women of childbearing potential must use highly effective contraception while taking lenvatinib (Lenvima®) and for one month after stopping treatment. It is currently unknown if lenvatinib (Lenvima®) increases the risk of thromboembolic events when combined with oral contraceptives.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Hypertension:** Hypertension has been reported in patients treated with lenvatinib (Lenvima®), usually occurring early in the course of treatment. Blood pressure should be well controlled prior to treatment with lenvatinib (Lenvima®) and, if patients are known to be hypertensive, they should be on a stable dose of antihypertensive therapy for at least 1 week prior to treatment with lenvatinib (Lenvima®). Serious complications of poorly controlled hypertension, including aortic dissection, have been reported. The early detection and effective management of hypertension are important to minimise the need for lenvatinib (Lenvima®) dose interruptions and reductions. Antihypertensive agents should be started as soon as elevated BP is confirmed. The choice of antihypertensive treatment should be individualised to the patient’s clinical circumstances and follow standard medical practice. For previously normotensive subjects, monotherapy with one of the classes of antihypertensives should be started when elevated BP is observed. For those patients already on antihypertensive medication, the dose of the current agent may be increased, if appropriate, or one or more agents of a different class of antihypertensive should be added. When necessary, manage hypertension as recommended in Table 3.
- **Aneurysms and artery dissections:** The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysms and/or artery dissections. Before initiating lenvatinib (Lenvima®), this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.
- **Renal failure and impairment:** Renal impairment and renal failure have been reported in patients treated with lenvatinib (Lenvima®). The primary risk factor identified was dehydration and/or hypovolemia due to gastrointestinal toxicity. Gastrointestinal toxicity should be actively managed in order to reduce the risk of development of renal impairment or renal failure. Dose interruptions, adjustments, or discontinuation may be necessary. If patients have severe renal impairment, the initial dose of lenvatinib (Lenvima®) should be adjusted (Ref Table 2).
- **Cardiac Failure:** Patients should be monitored for clinical symptoms or signs of cardiac decompensation, as dose interruptions, adjustments, or discontinuation may be necessary.

NCCP Regimen: Levatinib (Lenvima®) - DTC therapy	Published: 12/01/2016 Review: 12/04/2029	Version number: 6
Tumour Group: Head and Neck NCCP Regimen Code: 00295	IHS/ISMO Contributor: Dr Liam Grogan Prof Maccon Keane	Page 5 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at <http://www.hse.ie/eng/Disclaimer>
This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

- **PRES / RPLS:** PRES, also known as RPLS, has been reported in patients treated with lenvatinib (Lenvima®). In patients with signs or symptoms of PRES, dose interruptions, adjustments, or discontinuation may be necessary.
- **Hepatotoxicity:** Liver-related adverse reactions most commonly reported in patients treated with lenvatinib (Lenvima®) include increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood bilirubin. Hepatic failure and acute hepatitis (<1%) have been reported in patients with DTC treated with lenvatinib (Lenvima®). The hepatic failure cases were generally reported in patients with progressive metastatic liver metastases disease. Liver function tests should be monitored before initiation of treatment, then every 2 weeks for the first 2 months and monthly thereafter during treatment. In the case of hepatotoxicity, dose interruptions, adjustments, or discontinuation may be necessary. If patients have severe hepatic impairment, the initial dose of lenvatinib (Lenvima®) should be adjusted.
- **Haemorrhage:** Serious cases of haemorrhage have been reported in patients treated with lenvatinib (Lenvima®). Cases of fatal intracranial haemorrhage have been reported in some patients with or without brain metastases. Screening for and subsequent treatment of oesophageal varices in patients with liver cirrhosis should be performed as per standard of care before starting treatment with lenvatinib (Lenvima®). In the case of bleeding, dose interruptions, adjustments, or discontinuation may be necessary. The degree of tumour invasion/infiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe haemorrhage associated with tumour shrinkage/necrosis following lenvatinib (Lenvima®) therapy.
- **Gastrointestinal perforation or fistula:** These have been reported in patients treated with lenvatinib (Lenvima®) mostly in patients with risk factors such as prior surgery or radiotherapy. In the case of a gastrointestinal perforation or fistula, dose interruptions, adjustments, or discontinuation may be necessary.
- **QT Interval Prolongation:** Electrocardiograms should be monitored in all patients with a special attention for those with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, and those taking medicinal products known to prolong the QT interval, including Class Ia and III antiarrhythmics. Electrolyte disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia increase the risk of QT prolongation; therefore electrolyte abnormalities should be monitored and corrected in all patients before starting treatment. Periodic monitoring of ECG and electrolytes (magnesium, potassium and calcium) should be during treatment. Blood calcium levels should be monitored at least monthly and calcium should be replaced as necessary during lenvatinib (Lenvima®) treatment. Lenvatinib (Lenvima®) dose should be interrupted or dose adjusted as necessary depending on severity, presence of ECG changes, and persistence of hypocalcaemia.
- **Impairment of thyroid stimulating hormone suppression:** Lenvatinib (Lenvima®) impairs exogenous thyroid suppression. Thyroid stimulating hormone (TSH) levels should be monitored on a regular basis and thyroid hormone administration should be adjusted to reach appropriate TSH levels, according to the patient's therapeutic target.
- **Wound Healing Complications:** Impaired wound healing has been reported in patients receiving lenvatinib (Lenvima®). Temporary interruption of lenvatinib (Lenvima®) should be considered in patients undergoing major surgical procedures. The decision to resume lenvatinib (Lenvima®) following a major surgical procedure should be based on clinical judgment of adequate wound healing.
- **Osteonecrosis of the jaw (ONJ):** Invasive dental procedures are an identified risk factor. Prior to treatment with lenvatinib, a dental examination and appropriate preventive dentistry should be

NCCP Regimen: Lenvatinib (Lenvima®) - DTC therapy	Published: 12/01/2016 Review: 12/04/2029	Version number: 6
Tumour Group: Head and Neck NCCP Regimen Code: 00295	IHS/ISMO Contributor: Dr Liam Grogan Prof Maccon Keane	Page 6 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

considered. In patients who have previously received or are receiving intravenous bisphosphonates, invasive dental procedures should be avoided if possible.

DRUG INTERACTIONS:

- It is currently unknown whether lenvatinib (Lenvima®) may reduce the effectiveness of hormonal contraceptives, and therefore women using oral hormonal contraceptives should add a barrier method.
- Current drug interaction databases should be consulted for more information.

REFERENCES:

1. Schlumberger M, Tahara M et al. Lenvatinib versus Placebo in Radioiodine Refractory Thyroid Cancer. *New Engl J Med* 2015;372(7):621-630
2. Giraud E L, Lijster B D, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update. Available at: <https://pubmed.ncbi.nlm.nih.gov/37269847/>
3. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V5 2023. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
4. Lenvatinib (LENVIMA®) Summary of Product Characteristics. Accessed Feb 2021. Available at: https://www.ema.europa.eu/en/documents/product-information/lenvima-epar-product-information_en.pdf

Version	Date	Amendment	Approved By
1	12/01/2016	Initial Draft	Dr Liam Grogan
2	15/03/2017	Presentation of dosing in renal and hepatic impairment in tabular form. Updated dose modification schedule for adverse events	Prof Maccon Keane
3	12/02/2019	Updated regimen title. Updated baseline and regular testing required as per SmPC and emetogenic potential. Updated adverse effects /regimen specific complications as per SPC update	Prof Maccon Keane
4	07/10/2019	Updated adverse effects/regimen specific complications as per SmPC update on aneurysms and artery dissections Updated Hepatitis B reactivation management recommendations	Prof Maccon Keane
5	10/03/2021	Reviewed. Amended emetogenic potential and updated adverse effects.	Prof Maccon Keane

NCCP Regimen: Levatinib (Lenvima®) - DTC therapy	Published: 12/01/2016 Review: 12/04/2029	Version number: 6
Tumour Group: Head and Neck NCCP Regimen Code: 00295	IHS/ISMO Contributor: Dr Liam Grogan Prof Maccon Keane	Page 7 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

6	12/04/2024	<p>Reviewed. Added tradename Lenvima®. Updated treatment table with administration information. Removed virology screening information. Updated emetogenic potential. Updated renal and hepatic information in line with Giraud recommendations, 2023 and SmPC.</p>	Prof Maccon Keane
---	------------	--	-------------------

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

NCCP Regimen: Levatinib (Lenvima®) - DTC therapy	Published: 12/01/2016 Review: 12/04/2029	Version number: 6
Tumour Group: Head and Neck NCCP Regimen Code: 00295	IHS/ISMO Contributor: Dr Liam Grogan Prof Maccon Keane	Page 8 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens